Overview

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

Status:
Completed
Trial end date:
2021-01-04
Target enrollment:
Participant gender:
Summary
A Randomized double blind, placebo controlled study of BMS-986259 to evaluate the safety and effectiveness of the drug amongst different conditions and populations.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb